Format

Send to

Choose Destination
Curr Med Chem. 2019 May 17. doi: 10.2174/0929867326666190517115515. [Epub ahead of print]

B7-H3 immune checkpoint protein in human cancer.

Author information

1
Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet. PO Box 4950 Nydalen, N-0424 Oslo. Norway.

Abstract

B7-H3 belongs to the B7 family of immune checkpoint proteins, which are important regulators of the adaptive immune response and emerging key players in human cancer. B7-H3 is a transmembrane protein expressed on the surface of tumor cells, antigen presenting cells, natural killer cells, tumor endothelial cells, but can also be present in intra- and extracellular vesicles. Additionally, B7-H3 may be present as circulating soluble isoforms in serum and other body fluids. B7-H3 is overexpressed in a variety of tumor types, in correlation with poor prognosis. B7-H3 is a promising new immunotherapy target for anti-cancer immune response, as well as being a potential biomarker. Besides its immunoregulatory role, B7-H3 has intrinsic pro-tumorigenic activities related to enhanced cell proliferation, migration, invasion, angiogenesis, metastatic capacity and anti-cancer drug resistance. B7-H3 has also been found to regulate key metabolic enzymes, promoting the high glycolytic capacity of cancer cells. B7-H3 receptors are still not identified, and little is known about the molecular mechanisms underlying B7-H3 functions. Here, we review the current knowledge on the involvement of B7-H3 in human cancer.

KEYWORDS:

B7-H3 ; adaptive immune response ; anti-cancer ; anti-cancer drug resistance; immune checkpoint proteins

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center